| Name | PS210 |
| Description | PS210 is a potent and selective activator of PDK1 (Kd: 3 μM), specifically targeting the PIF-binding pocket of PDK1 without affecting other protein kinases such as S6K, PKB/Akt, or GSK3. Its prodrug, PS423, serves as a substrate-selective inhibitor of PDK1 in cells, inhibiting the phosphorylation and activation of S6K. |
| In vitro | PS210 stabilized the residue Arg131 when PS210 causes stabilization of PDK1 to the temperature gradient, located opposite to the helix a-B at the other extreme of the helix a-C. So, the residues forming part of the phosphate-binding site appear to be a fixed point that allows for the relative movement of the helices in the process of PDK1 activation[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (157.77 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.26 mM), Sonication is recommended.
|
| Keywords | Thr148 | S6K | PS423 | PS-210 | PS210 | PS 210 | pocket | PIFtide | PIF-binding | PDK-1 | PDK1 | Lys76 | Inhibitor | inhibit | helix | Arg131 | a-B |
| Inhibitors Related | Rabusertib | MP7 | M77976 | Sodium dichloroacetate | RS1-PDK1 inhibitor | GSK-7227 | BX795 | Hordenine hydrochloride | Dehydroabiethylamine | Dicoumarol | Osu03012 | PS423 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Autophagy Compound Library | Anti-Breast Cancer Compound Library | Anti-Obesity Compound Library | Antioxidant Compound Library | Neuroprotective Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
